Nasdaq:NSPR
InspireMD, Inc.
A clinical-stage biopharmaceutical firm developing novel therapies for rare neuromuscular diseases with a substantial cash position but currently operating at a net loss.
Key Metrics
Investment Thesis
Bull Case
Insiders may view the expanding revenue base and growing market opportunity in rare disease therapies as a catalyst for future profitability once key drug candidates reach commercialization milestones. The company's strong liquidity position allows it to weather near-term losses while building a pipeline that could command significant value upon approval. Potential licensing deals or strategic partnerships could provide non-dilutive funding and accelerate time-to-market for breakthrough therapies.
Bear Case
The widening net loss trend and negative operating cash flow suggest the company is burning through its resources faster than it can generate sustainable earnings, raising concerns about long-term survival without major external capital raises. High general and administrative expenses coupled with significant R&D spending have not yet translated into revenue growth commensurate with the scale of investment made. Investors face substantial dilution risk as the company continues to operate at a deficit with no visible path to profitability in the near term.
About InspireMD, Inc.
InspireMD, Inc. (NSPR) is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, specifically targeting conditions like Duchenne Muscular Dystrophy and other neuromuscular disorders. The company operates within the specialized medical device and pharmaceutical sectors, serving patients globally through its pipeline of innovative treatments. With significant cash reserves and a history of strategic financing, NSPR aims to bridge gaps in current therapeutic options for underserved patient populations.
Analysis
Management Discussion
Despite a 35% increase in revenue from $5.2M in 2022 to $7.0M in 2024, the company's financial health is deteriorating as net losses have nearly doubled over the same period. Operating cash flow turned negative at -$21.9M while capital expenditures reached $1.4M, suggesting aggressive spending on R&D that is not yet generating proportional returns. The substantial cash burn requires successful product launches or strategic partnerships to avoid further dilution of shareholder equity.
Industry Overview
The rare disease therapeutic market is characterized by high development costs, long regulatory approval timelines, and significant financial risk for biotech firms targeting small patient populations. While competition exists from large pharmaceutical companies and other biotechs, the niche nature of these diseases often allows specialized players to carve out protected markets with limited direct comparators. Success in this sector typically hinges on clinical trial success rates and the ability to secure government or insurance reimbursement for expensive treatments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $5.2M | $6.2M | $7.0M |
| Cost of Revenue | $4.1M | $4.4M | $5.5M |
| Gross Profit | $1.1M | $1.8M | $1.5M |
| Operating Expenses | $19.8M | $22.9M | $35.0M |
| Operating Income | $-18.7M | $-21.1M | $-33.5M |
| R&D | $7.8M | $8.0M | $13.6M |
| G&A | $8.4M | $11.1M | $15.3M |
| Marketing | $3.7M | $3.9M | $6.1M |
| Stock-Based Comp | $2.4M | $4.5M | $10.1M |
| D&A | $188.0K | $232.0M | $280.0M |
| Depreciation | — | $232.0K | $280.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $250.0K | $1.3M | $1.6M |
| Pre-Tax Income | $-18.5M | $-19.9M | $-31.9M |
| Income Tax | $28.0K | $65.0K | $59.0K |
| Continuing Ops | $-18.5M | $-19.9M | $-32.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.5M | $-19.9M | $-32.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.5M | $-19.9M | $-32.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $21.3M | $44.2M | $40.5M |
| Cash & Equivalents | $4.6M | $9.6M | $18.9M |
| Marketable Securities | — | $29.4M | $15.7M |
| Accounts Receivable | $1.0M | $1.8M | $1.6M |
| Inventory | $1.6M | $2.1M | $2.6M |
| Other Current Assets | $14.0M | $1.2M | $1.7M |
| Long-Term Assets | $3.3M | $3.5M | $6.3M |
| PP&E (Net) | $917.0K | $1.1M | $2.4M |
| Operating Leases | $1.6M | $1.5M | $2.4M |
| Other LT Assets | $856.0K | $951.0K | $1.6M |
| Total Assets | $24.7M | $47.6M | $46.8M |
| Current Liabilities | $5.1M | $6.0M | $7.7M |
| Current Leases | $419.0K | $557.0K | $542.0K |
| Other Current Liab | $4.1M | $4.3M | $5.8M |
| Long-Term Liabilities | $2.2M | $2.1M | $3.0M |
| LT Operating Leases | $1.2M | $1.0M | $1.8M |
| Other LT Liab | $995.0K | $1.1M | $1.2M |
| Total Liabilities | $7.3M | $8.1M | $10.7M |
| Shareholders' Equity | $17.4M | $39.5M | $36.1M |
| Paid-In Capital | $219.0M | $261.0M | $289.6M |
| Retained Earnings | $-201.6M | $-221.5M | $-253.5M |
| Total L&E | $24.7M | $47.6M | $46.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-18.5M | $-19.9M | $-32.0M |
| Non-Cash Adjustments | $1.9M | $1.1M | $7.9M |
| Working Capital Changes | $1.1M | $2.4M | $2.2M |
| Cash from Operations | $-15.5M | $-16.4M | $-21.9M |
| Capital Expenditures | $473.0K | $381.0K | $1.4M |
| Cash from Investing | $8.4M | $-16.1M | $12.6M |
| Cash from Financing | $-140.0K | $37.5M | $18.5M |
| FX Effect | $-131.0K | $-58.0K | $51.0K |
| Net Change in Cash | $-7.4M | $5.0M | $9.3M |
| Beginning Cash | $12.0M | $4.6M | $9.6M |
| Ending Cash | $4.6M | $9.6M | $18.9M |
Frequently Asked Questions
How does InspireMD, Inc. make money?
The company's revenue is primarily derived from product sales and licensing agreements related to its proprietary drug candidates, supported by operational activities in research, development, and commercialization of treatments for rare genetic conditions. While specific segment breakdowns are limited in the public filings, revenue streams likely include direct patient access programs and potential partnership royalties.
What are the main risks for NSPR?
Significant operating losses widening from -$18.5M in 2022 to -$32.0M in 2024 indicate unsustainable burn rates without successful commercial milestones; reliance on external financing due to negative cash flow from operations of $-21.9M; potential failure of clinical trials leading to pipeline devaluation; and limited revenue growth compared to the deepening deficit.
What is NSPR's competitive advantage?
First-mover advantage in developing specialized therapies for rare diseases with high unmet medical need; a robust balance sheet providing $18.9M in cash to fund R&D without immediate dilution pressure; and a focused pipeline targeting specific neuromuscular conditions where few or no approved treatments exist.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.